WESTBROOK, Maine, Dec. 22, 2022 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, will participate in the Goldman Sachs Healthcare CEOs Unscripted Conference on Thursday, January 5, 2023. Jay Mazelsky, President and Chief Executive Officer will participate in a fireside chat at 1:15 pm ET.
Individuals can access the live audio webcast of the presentation through a link on the IDEXX website, www.idexx.com/investors. An archived edition of the presentation will be available via the same link.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P 500® Index. Headquartered in Maine, IDEXX employs more than 10,000 people and offers solutions and products to customers in more than 175 countries. For more information about IDEXX, visit idexx.com.
Contact:
Investor Relations
John Ravis
1-207-556-8155
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$432.36 |
| Daily Change: | 5.10 1.19 |
| Daily Volume: | 573,187 |
| Market Cap: | US$35.400B |
October 31, 2024 August 21, 2024 August 06, 2024 June 04, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
